Showing 4081-4090 of 8644 results for "".
- Ceramide and Niacinamide-Containing Moisturizer Safe, Effective with Topical Acne Treatmenthttps://practicaldermatology.com/news/study-reveals-ceramide-and-niacinamide-containing-moisturizer-enhances-topical-acne-treatment/2462234/New research suggests that a moisturizer containing ceramides and niacinamide (CCM) significantly improved lesions from acne vulgaris when combined with anti-acne medication. "Dermatologists often suggests using moisturizers for a wide range of skin problems initiated by acne
- Analysis Reveals Pre- and Post-COVID-19 Teledermatology Usage and Barriershttps://practicaldermatology.com/news/teledermatology-platforms-usage-and-barriers-a-cross-sectional-analysis-of-united-states-based-dermatologists-pre-and-post-covid-19/2462231/Dermatologists have increasingly turned to teledermatology to enhance patient care, but a recent study highlights crucial disparities in platform usage and functionality among practitioners. Researchers used cross-sectional pre-validated survey in 2021 and sought to discern va
- YCANTH Receives Permanent J-Code Status from CMShttps://practicaldermatology.com/news/ycanth-receives-permanent-j-code-from-cms/2462230/The Centers for Medicare and Medicaid Services (CMS) have granted a permanent J-code (J7354) for YCANTH, the only FDA-approved treatment for molluscum contagiosum.
- Benzoyl Peroxide 2.6% Cleanser Effective at Reducing Acne Lesionshttps://practicaldermatology.com/news/benzoyl-peroxide-26-cleanser-effective-at-reducing-acne-lesions/2462228/A benzoyl peroxide 2.6% (BPO) complexion clearing acne cleanser (CCAC) was effective at reducing acne, a new study reports.
- Guselkumab Demonstrates Significant and Rapid Scalp Psoriasis Clearance in People of Colorhttps://practicaldermatology.com/news/tremfya-guselkumab-demonstrates-significant-and-rapid-scalp-psoriasis-clearance-in-people-of-color-in-new-large-phase-3b-study/2462218/At the Maui Derm Hawaii 2024 conference, Johnson & Johnson presented topline data from Cohort B in the Phase 3b VISIBLE study that demonstrated that TREMFYA® (guselkumab) showed rapid and significant clearance in moderate to severe scalp psoriasis (PsO) and significant improvement
- New Assessment Tool for Chronic Prurigo Shows Power of Patient Reportinghttps://practicaldermatology.com/news/development-and-validation-of-a-patient-reported-outcome-measure-to-assess-disease-control-in-chronic-prurigo/2462214/Researchers have introduced a 5-item Prurigo Control Test (PCT), in what could be the first patient-reported outcome measure for determining disease control for chronic prurigo (CPG). This tool, according to the researchers, was designed to assess disease control in CPG
- Insufficient Disease Control in Moderate-to-Severe AD: Year-long Longitudinal Study Reveals Treatment Gapshttps://practicaldermatology.com/news/insufficient-disease-control-in-severe-atopic-dermatitis-a-12-month-longitudinal-study-reveals-treatment-gaps/2462212/A recent study presented at the Revolutionizing Atopic Dermatitis (RAD) Virtual Conference highlighted has shed light on the persistent issue of therapeuti
- Skin Deep Solutions: Navigating Acne and Rosacea with Quality Skin Carehttps://practicaldermatology.com/news/skin-deep-solutions-navigating-acne-and-rosacea-with-quality-skin-care/2462209/In the ever-evolving landscape of dermatology, Hilary Baldwin, MD, a board-certified dermatologist, and the medical director of the Acne Treatment & Research Center in Brooklyn, recently shed light on the critical role
- Navigating Antibiotic Use for Acne and Rosacea: Clinician Insights and Considerationshttps://practicaldermatology.com/news/navigating-antibiotic-use-for-acne-and-rosacea-clinician-insights-and-considerations/2462208/Growing apprehensions surrounding antibiotic resistance in acne and rosacea treatments, coupled with their linked
- Novartis Set to Acquire Calypso Biotech, Focused on IL-15 Targeted Therapieshttps://practicaldermatology.com/news/novartis-set-to-acquire-calypso-biotech-focused-on-il-15-targeted-therapies/2462204/European-based biotech manufacturer Calypso has entered into an agreement to be acquired by Novartis, according to a press release. "We are excited for this transaction with Novartis," Calypso CEO and Founder Alain Vicari said in a news release. "As part of the